Figure 1.

Summary of readcount data obtained for ten somatic mutations and two validated SNPs in the AML primary tumor, AML relapse tumor and normal skin specimens. As described in the text, all heterozygous mutations were determined by readcount data to be present at around 50% prevalence in the tumor cells with the exception of the FLT3 internal tandem duplication mutant. The variant alleles in the primary and relapse tumor samples are statistically different from that of the skin sample for all mutations. Note that the normal skin sample was contaminated with leukemic cells containing the somatic mutations, as the patient's white blood cell count was 105 000 when the skin punch biopsy was obtained.